Rhovac ApS Company

RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells.

Investors

Technology: Peptides and Proteins
Industry: Peptides and Proteins
Headquarters: Hørsholm, Hovedstaden, Denmark
Founded Date: 2008-01-01
Employees Number: 11-50
Investors Number: 1
Total Funding: 85000000
Estimated Revenue: $1M to $10M
Last Funding Date: 2019-08-22
Last Funding Type: Grant

Visit Website
alj@rhovac.com
https://twitter.com/ultimovacs?lang=en
Register and Claim Ownership